1. Home
  2. RZLT vs EDD Comparison

RZLT vs EDD Comparison

Compare RZLT & EDD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RZLT
  • EDD
  • Stock Information
  • Founded
  • RZLT 2010
  • EDD 2007
  • Country
  • RZLT United States
  • EDD United States
  • Employees
  • RZLT N/A
  • EDD N/A
  • Industry
  • RZLT Biotechnology: Pharmaceutical Preparations
  • EDD Finance Companies
  • Sector
  • RZLT Health Care
  • EDD Finance
  • Exchange
  • RZLT Nasdaq
  • EDD Nasdaq
  • Market Cap
  • RZLT 819.3M
  • EDD 329.4M
  • IPO Year
  • RZLT N/A
  • EDD N/A
  • Fundamental
  • Price
  • RZLT $9.57
  • EDD $5.32
  • Analyst Decision
  • RZLT Strong Buy
  • EDD
  • Analyst Count
  • RZLT 7
  • EDD 0
  • Target Price
  • RZLT $14.86
  • EDD N/A
  • AVG Volume (30 Days)
  • RZLT 1.5M
  • EDD 254.3K
  • Earning Date
  • RZLT 11-07-2025
  • EDD 01-01-0001
  • Dividend Yield
  • RZLT N/A
  • EDD 7.52%
  • EPS Growth
  • RZLT N/A
  • EDD N/A
  • EPS
  • RZLT N/A
  • EDD N/A
  • Revenue
  • RZLT N/A
  • EDD N/A
  • Revenue This Year
  • RZLT N/A
  • EDD N/A
  • Revenue Next Year
  • RZLT N/A
  • EDD N/A
  • P/E Ratio
  • RZLT N/A
  • EDD N/A
  • Revenue Growth
  • RZLT N/A
  • EDD N/A
  • 52 Week Low
  • RZLT $2.22
  • EDD $4.22
  • 52 Week High
  • RZLT $10.04
  • EDD $4.95
  • Technical
  • Relative Strength Index (RSI)
  • RZLT 57.58
  • EDD 46.96
  • Support Level
  • RZLT $8.55
  • EDD $5.32
  • Resistance Level
  • RZLT $10.03
  • EDD $5.40
  • Average True Range (ATR)
  • RZLT 0.58
  • EDD 0.06
  • MACD
  • RZLT -0.04
  • EDD 0.00
  • Stochastic Oscillator
  • RZLT 69.85
  • EDD 52.44

About RZLT Rezolute Inc. (NV)

Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.

About EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.

Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.

Share on Social Networks: